Successful treatment of non-small-cell lung cancer with afatinib and a glucocorticoid following gefitinib- and erlotinib-induced interstitial lung disease: A case report
Tetsuo Tani(Keio University), Tomoko Betsuyaku(Tokyo Medical University), Keita Masuzawa(Kitasato Institute Hospital), Aoi Kuroda(Keio University), Takanori Asakura(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Hanako Hasegawa(Keio University), Katsuhiko Naoki(Broad Institute), Shoji Suzuki(Keio University), Kenzo Soejima(Keio University), Toshiyuki Hirano(Sapporo Kosei General Hospital), Makoto Ishii(Tokyo Medical and Dental University)
Cited by 7
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565